bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
58%Questions answered3Evaded / deflected12Questions auditedContradictedNumbers vs filing
Partial answer
High priority
What drove the sequential US revenue growth?
Asked by Kunal Dhamesha, Macquarie
CEO listed drivers but gave no order of magnitude or split.
no quantitative breakdown
Read the exchange
Question
Would you be able to give us some color as to which were the primary driver? Was it the acquisition, was it the lenalidomide uptake?
Erez Israeli, CEO
This quarter, we had several growth engines, so it's not just in lenalidomide. We grew market share in key products... We had the Mayne acquisitions that contributed and Lena. It's a combination of all of them.
Answered
Medium priority
Will reduced price erosion continue?
Asked by Kunal Dhamesha, Macquarie
CEO gave a clear near-term outlook.
Read the exchange
Question
Do you see that this reduced price erosion to continue for some time, or is it more of a transitory phenomena?
Erez Israeli, CEO
I believe that in our case, we probably will see something similar also in the next coming quarter.
Partial answer
Medium priority
Are supply opportunities in US sustainable?
Asked by Damayanti Kerai, HSBC
CEO described drivers but did not commit to duration beyond 'trend will continue'.
no quantificationvague on sustainability
Read the exchange
Question
Can you elaborate bit more whether you are seeing lot of supply opportunities emerging in the market... Do you believe these opportunities will sustain for next two quarters?
Erez Israeli, CEO
It's a combination of timing of RFPs... Overall, let's say it's primarily a volume-based growth that based on agreements with certain customers.
Evasive
High priority
How will EBITDA margins move excluding Revlimid?
Asked by Damayanti Kerai, HSBC
CEO declined to answer excluding Revlimid, stuck to overall 25% target.
refused to exclude Revlimidrepeated long-term guidance
Read the exchange
Question
How do you see your EBITDA margins moving up in next two years, excluding Revlimid, if you can provide some color on it?
Erez Israeli, CEO
I'm still maintaining the long-term average of the 25%, 25%... likely that it will be above the threshold of 25%.
Evasive
High priority
What was Mayne portfolio's size and profitability this quarter?
Asked by Surya Narayan Patra, PhillipCapital India Pvt Ltd
CEO did not provide size or profitability, only said next quarter will be bigger.
no numbers givendeferred to next quarter
Read the exchange
Question
What is the kind of size that we would have seen this quarter out of that? Also, if you can give some clarity about the profitability of this portfolio?
Erez Israeli, CEO
We closed the deal and practically started to sell in the end of April... the contribution of Mayne will be more significant in the next quarter to come than it came in this quarter.
Declined
High priority
Will lenalidomide volume share improve progressively?
Asked by Surya Narayan Patra, PhillipCapital India Pvt Ltd
CEO explicitly declined to share volume or trajectory due to agreement.
refused to share volumecited confidentiality
Read the exchange
Question
Is it fair to believe this is the kind of first year number, and we should see a progressive improvement in the volume share going ahead?
Erez Israeli, CEO
I cannot share them as per our agreement. What I can say is, this kind of levels of sales of lenalidomide is likely to continue and fluctuate from quarter to quarter.
Answered
Medium priority
What drove India business growth and how much from trade generics?
Asked by Neha Manpuria, Bank of America
CEO clearly stated trade generics had minimal contribution and attributed growth to brand generics.
Read the exchange
Question
Was there any contribution at all of the trade generic business in the first quarter? If you could give us some color in terms of what's driving the improvement.
Erez Israeli, CEO
The trade generic did not yet contribute much because we just recently launched it. Most of the growth happened from our brand generics, our key brands.
Partial answer
Medium priority
When will China contribute meaningfully to EM revenue?
Asked by Neha Manpuria, Bank of America
CEO gave a timeline but no quantitative contribution.
no specific revenue targetdeferred to FY25
Read the exchange
Question
When do we see meaningful contribution start from China, or when do we see how does the step up from this level happen in the emerging market business?
Erez Israeli, CEO
We are now starting to see the results, so likely that this trend of approvals will continue. The most of the values we start to see... more significant growth in FY 2025.
Answered
Medium priority
Why did trade receivables jump INR 400-450 crore?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
CEO explained it as normal business growth, no channel stuffing.
Read the exchange
Question
Is this more or less linked to North America business? Is this more to fill up the channel and so the sales could moderate to some extent in the coming quarters?
Erez Israeli, CEO
The increase in the receivables is broadly in line with the growth in business and the normal fluctuations... There is nothing unusual.
Answered
High priority
What is the gross margin guidance for future?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
CEO provided a clear range.
Read the exchange
Question
If you could just indicate the gross margin guidance, for say, future?
Erez Israeli, CEO
Overall, I expect our gross margin to range between 50%-59% in the next few quarters.
Partial answer
High priority
How will Dr. Reddy's achieve top 5 in India with divestments?
Asked by Shyam Srinivasan, Goldman Sachs
CEO explained strategy but gave no concrete product pipeline details.
no specific product examplesvague on timeline
Read the exchange
Question
How do we get to top five if you keep divesting? You mentioned innovation to help you double, but I'm just wondering, what are these opportunities?
Erez Israeli, CEO
The way to do that for us is by launching innovation... we can be top five even without.
Answered
Medium priority
What is China revenue base and growth trajectory?
Asked by Saion Mukherjee, Nomura
CEO gave current base and a clear growth target.
Read the exchange
Question
What's the revenue base in China currently? ...how should you think about revenue in China in three years' time?
Erez Israeli, CEO
I see any number of around 2x in the next three years. The baseline... is around $180 million a year.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Long-term EBITDA margin target of 25% | 25% | 31.7% | Understated vs filing |
| Gross margin expected between 50%-59% next few quarters | 50% | 31.7% | Overstated vs filing |
| China revenue base around $180 million per year | 180 | 6,738 | Understated vs filing |
| China revenue expected to double in three years | 2 | 29 | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.